The Lenacapavir HIV Prevention Injection is a long-acting form of pre-exposure prophylaxis, commonly known as PrEP, developed to reduce the risk of acquiring HIV. Lenacapavir works differently from several established HIV medicines because it targets the HIV capsid, a protein structure that plays multiple roles in the virus's life cycle. Its long-lasting activity allows injections to be administered at extended intervals rather than requiring a daily prevention medicine. Interest in Lenacapavir for HIV Prevention increased following results from large clinical trials evaluating its effectiveness and safety in different populations.
In June 2025, the U.S. Food and Drug Administration approved injectable lenacapavir for HIV PrEP, and in July 2025, the World Health Organization recommended twice-yearly injectable lenacapavir as an additional PrEP option within combination HIV prevention approaches. These developments expanded the range of Injectable HIV Prevention Options available or being introduced through health systems worldwide.
Lenacapavir HIV Prevention is intended for use as pre-exposure prophylaxis. PrEP refers to medication used by people who do not have HIV to reduce their likelihood of acquiring the virus. Unlike HIV treatment, which is used by people living with HIV, prevention-focused PrEP is taken before potential exposure and requires appropriate HIV testing and clinical assessment.
Lenacapavir belongs to a class of medicines known as capsid inhibitors. The HIV capsid is a protein shell surrounding important viral genetic material and enzymes. Lenacapavir interacts with this capsid and interferes with several processes involved in the HIV life cycle. Its pharmacological properties allow the medicine to remain active in the body for an extended period, making it suitable for a Long Acting HIV Prevention Injection approach.
The Lenacapavir Prevention Injection is administered subcutaneously, meaning the medicine is injected into the tissue beneath the skin. In the approved U.S. prevention regimen, lenacapavir injections are administered every six months following an initiation schedule. CDC guidance recommends injectable lenacapavir every six months as a PrEP option for people weighing at least 35 kilograms who would benefit from PrEP.
The extended dosing interval distinguishes Lenacapavir Injectable HIV Prevention from daily oral PrEP and from long-acting injectable cabotegravir, which uses a different dosing schedule. WHO describes lenacapavir as the first twice-yearly injectable PrEP option. However, receiving fewer doses does not eliminate the need for follow-up care, HIV testing, appropriate clinical monitoring, and timely administration of scheduled injections.
HIV testing is an important part of PrEP care. A person starting or continuing PrEP needs appropriate testing to confirm that they do not have HIV. This is particularly relevant for long-acting medicines because drug concentrations can remain in the body for an extended period.
WHO guidance on Long Acting HIV Prevention includes recommendations concerning HIV testing for people initiating or continuing injectable PrEP. WHO recommends a public-health testing approach using HIV rapid diagnostic tests to support delivery of long-acting injectable PrEP, including lenacapavir and cabotegravir. Testing practices may vary according to national guidelines, available diagnostic methods, and individual clinical circumstances.
Clinical evidence for the Lenacapavir HIV Prevention Injection includes the PURPOSE 1 and PURPOSE 2 randomized controlled trials. According to the CDC's evidence review, the studies reported 100 percent efficacy among female participants in PURPOSE 1 and 96 percent efficacy in the primarily male PURPOSE 2 population when compared with estimated background HIV incidence over approximately 52 weeks. These findings formed part of the evidence considered in clinical recommendations.
Clinical trial percentages should be interpreted within the design, populations, follow-up periods, and comparison methods used in each study. They do not mean that any prevention method can guarantee that an individual will never acquire HIV. Consistent participation in the prescribed regimen and appropriate testing remain important aspects of PrEP care.
Safety assessments are an important component of evaluating Lenacapavir for HIV Prevention. In the clinical trials reviewed by the CDC, no significant safety concerns were identified, and the most commonly reported adverse events were mild to moderate injection-site reactions.
Injection-site reactions can include localized effects associated with receiving medication beneath the skin. Individual experiences can differ, and health professionals consider a person's medical history, current medicines, possible interactions, and other relevant factors when determining whether a particular HIV Prevention Injection is appropriate.
Because lenacapavir remains in the body for a prolonged period, following the recommended dosing and follow-up schedule is an important consideration. People considering or using long-acting PrEP should receive guidance based on the prescribing information and HIV prevention recommendations applicable in their location.
Modern HIV prevention includes several PrEP approaches rather than one method that is appropriate for everyone. Injectable HIV Prevention Options include long-acting formulations designed to reduce the frequency with which a person needs to take medication compared with daily oral PrEP.
Lenacapavir and cabotegravir are different medicines with different mechanisms and dosing schedules. Lenacapavir is a capsid inhibitor administered every six months for PrEP under current U.S. recommendations, while long-acting cabotegravir is another injectable PrEP option administered more frequently. Oral PrEP continues to be an established option as well. WHO emphasizes that providing different PrEP choices can help individuals select approaches suited to their circumstances and preferences.
A Long Acting HIV Prevention Injection is one component of HIV prevention rather than a replacement for every other preventive measure. WHO recommends lenacapavir as an additional choice within combination HIV prevention approaches. Depending on individual circumstances, broader prevention can include HIV and sexually transmitted infection testing, condoms, harm-reduction measures, and appropriate medical care.
PrEP medicines prevent HIV acquisition when used appropriately but do not generally prevent other sexually transmitted infections. For this reason, HIV prevention discussions may consider several strategies according to a person's health needs, potential exposures, preferences, and clinical circumstances.
The availability of Lenacapavir Injectable HIV Prevention can differ between countries because regulatory authorization, national guidelines, procurement systems, healthcare infrastructure, and local implementation policies vary. FDA approval in the United States and WHO recommendations provide important regulatory and public-health frameworks, but they do not mean that the medicine is automatically available through every healthcare system.
Implementing twice-yearly PrEP also requires systems for HIV testing, scheduled administration, follow-up, supply management, and appropriate clinical assessment. These considerations are part of the broader discussion surrounding long-acting prevention technologies.
The Lenacapavir HIV Prevention Injection represents an additional development in PrEP by combining a capsid-inhibiting medicine with a twice-yearly injection schedule. Current evidence and international guidance support its role as an additional prevention option for eligible people, while appropriate HIV testing, scheduled dosing, clinical monitoring, and consideration of other prevention measures remain central to its use. As Long Acting HIV Prevention continues to develop, choices among oral and injectable approaches can be considered according to established clinical guidance and individual circumstances.